Clinical study on the concurrent treatment of brain and heart in treatment of chronic insomnia based on infrared thermography technology

INTERVENTION: Experimental group:Test group:Guipi Anshuiyin Granules, Specification : 17 grams per bag, oral, 2 bags each time, 2 times a day;The control group:Control group:Guipi Anshuiyin granules simulating agent,Specification : 17 grams per bag, oral, 2 bags each time, 2 times a day ; CONDITION: insomnia PRIMARY OUTCOME: Pittsburgh sleep quality index, PSQI; SECONDARY OUTCOME: infrared thermal imaging examination;fatigue scale‐14;hyperarousal scale, HAS;Insomnia severity index, ISI;TCM symptom score; INCLUSION CRITERIA: 1. Meet the diagnostic criteria for chronic insomnia in Western medicine; 2. Meet the standard of deficiency syndrome of heart and spleen in traditional Chinese medicine. 3. Be between 20‐65 years old (including 20 and 65 years old), regardless of gender; 4. Pittsburgh Sleep Quality Inde XScale (PSQI) score >7 points; 5. Have not received insomnia‐related treatment 1 week before treatment. 6. Be able to complete various scoring scales independently. 7. Those who voluntarily participate in this trial and sign an informed consent form. 8. Those who have participated in clinical trials of other drugs in the past 1 month; 9. Strictly adhere to the treatment methods prescribed in this study, obey the doctor's arrangement, and be able to cooperate with treatment and follow‐up visits.